Breaking News, Trials & Filings

Five Prime Therapeutics Submits IND Application

For Novel B7-H4 Antibody FPA150

Five Prime Therapeutics has submitted an Investigational New Drug (IND) application for FPA150, a first-in-class immuno-oncology antibody that targets B7-H4.    FPA150 was discovered using the company’s protein therapeutics platform and anticipates initiating a Phase 1 trial of FPA150 during the first half of 2018.   FPA150 is a high affinity, afucosylated monoclonal antibody designed with a dual mechanism of action: blocking a T cell checkpoint pathway and delivering enhanced an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters